Steven Kao
Overview
Explore the profile of Steven Kao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shahnam A, Davis A, Brown L, Sullivan I, Lin K, Ng C, et al.
Lung Cancer
. 2025 Feb;
201:108421.
PMID: 39977966
Background: KRAS G12D and G12C mutations have distinct biological traits influencing treatment response. This study examines real-world demographics, clinical characteristics, and first-line treatment outcomes in metastatic non-small-cell lung cancer (NSCLC)...
2.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S, et al.
Front Oncol
. 2025 Feb;
14:1544394.
PMID: 39957803
[This corrects the article DOI: 10.3389/fonc.2024.1376551.].
3.
Shi H, Yu T, Johnson B, Selvamani S, Zhuang L, Lee K, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):51.
PMID: 39939955
Background: Finding effective and curative treatment for mesothelioma remains challenging. While the introduction of immunotherapy combinations using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have offered hope for some patients, a large...
4.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S, et al.
Front Oncol
. 2024 Nov;
14:1376551.
PMID: 39534099
Background: Transforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface...
5.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, et al.
JTO Clin Res Rep
. 2024 Sep;
5(9):100703.
PMID: 39309618
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment...
6.
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, et al.
Lung Cancer
. 2024 Sep;
196:107924.
PMID: 39306923
Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of first-line atezolizumab or placebo plus carboplatin/etoposide in...
7.
Shrestha P, Kao S, Cheung V, Cooper W, van Zandwijk N, Rasko J, et al.
Mol Oncol
. 2024 Jul;
PMID: 38956984
Small cell lung cancer (SCLC) is a highly aggressive cancer with a dismal 5-year survival of < 7%, despite the addition of immunotherapy to first-line chemotherapy. Specific tumor biomarkers, such...
8.
Ke H, Kao S, van Zandwijk N, Rasko J, Yeo D
Lung Cancer
. 2024 May;
192:107829.
PMID: 38810528
Asbestos-Related Lung Cancer (ARLC) presents ongoing diagnostic challenges despite improved imaging technologies. The long latency period, coupled with limited access to occupational and environmental data along with the confounding effects...
9.
Smith S, Kao S, Boyer M, Franco M, Moore M
Intern Med J
. 2024 Apr;
54(8):1337-1343.
PMID: 38622825
Background: Lung cancer is the leading cause of cancer death in Australia. Immunotherapy has improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC). Pembrolizumab is approved in first-line...
10.
Tan L, Brown C, Mersiades A, Lee C, John T, Kao S, et al.
Nat Commun
. 2024 Feb;
15(1):1823.
PMID: 38418463
In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC)...